A phase 1, randomized, dose‐ranging study of GS ‐5816, a once‐daily NS 5A inhibitor, in patients with genotype 1–4 hepatitis C virus-Reference-Cited by-同舟云学术

A phase 1, randomized, dose‐ranging study of GS ‐5816, a once‐daily NS 5A inhibitor, in patients with genotype 1–4 hepatitis C virus

Published:2015-07-16 Issue:12 Volume:22 Page:1011-1019
ISSN:1352-0504
Container-title:Journal of Viral Hepatitis
language:en
Short-container-title:J Viral Hepat

Author:

Lawitz E.¹,Freilich B.²,Link J.³,German P.³,Mo H.³,Han L.³,Brainard D. M.³,McNally J.³,Marbury T.⁴,Rodriguez‐Torres M.⁵

Affiliation:

1. Texas Liver Institute University of Texas Health Sciences Center San Antonio TX USA

2. Kansas City Gastroenterology and Hepatology Kansas City MO USA

3. Gilead Sciences, Inc. Foster City CA USA

4. Orlando Clinical Research Center Orlando FL USA

5. Fundacion De Investigacion San Juan Puerto Rico

Funder

Gilead Sciences

Medtronic

Merck

Novartis

Roche

Human Genome Sciences

Johnson and Johnson

Boehringer Ingelheim

Bristol-Myers Squibb

GlaxoSmithKline

Publisher

Wiley

Subject

Virology,Infectious Diseases,Hepatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jvh.12435

Reference15 articles.

1. World Health Organization (WHO).Hepatitis C Fact sheet. Available at:http://www.who.int/mediacentre/factsheets/fs164/en/#. (accessed 3 September 2014).

2. Changing trends in hepatitis C-related mortality in the United States, 1995-2004

3. Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: Updated criteria and genotype assignment web resource

4. Global epidemiology and genotype distribution of the hepatitis C virus infection

5. Hepatitis C, A Global Issue: Access to Care and New Therapeutic and Preventive Approaches in Resource-Constrained Areas

Cited by 51 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Personalized care approaches to hepatitis C therapy: recent advances and future directions;Expert Review of Anti-infective Therapy;2024-03-11

2. Curing Hepatitis C with Direct‐Acting Antiviral Therapy;New Drug Development for Known and Emerging Viruses;2021-12-03

3. Efficacy and Safety of Sofosbuvir and Velpatasvir Combination for the Treatment of Chronic Hepatitis C in Patients With or Without Cirrhosis;Cureus;2021-11-20

4. Virological Factors Associated with Failure to the Latest Generation of Direct Acting Agents (DAA) and Re-Treatment Strategy: A Narrative Review;Viruses;2021-03-08

5. Prophylaxe, Diagnostik und Therapie der Hepatitis-C-Virus(HCV)-Infektion;Zeitschrift für Gastroenterologie;2020-11